Role of Integrin Alpha4 in Drug Resistance of Leukemia

Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF- B mediates chemoresistance

(2014) R. Jacamo et al.   BLOOD

Reversal Effect of ST6GAL 1 on Multidrug Resistance in Human Leukemia by Regulating the PI3K/Akt Pathway and the Expression of P-gp and MRP1

(2014) Hongye Ma et al.   PLoS One

Talin and kindlin: the one-two punch in integrin activation

(2014) Feng Ye et al.   Frontiers of Medicine

Integrin activation by P-Rex1 is required for selectin-mediated slow leukocyte rolling and intravascular crawling

(2013) J. M. Herter et al.   BLOOD

Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy

(2013) Y.-T. Hsieh et al.   BLOOD

How Natalizumab Binds and Antagonizes α4Integrins

(2013) Yamei Yu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Small Molecule Agonist of Very Late Antigen-4 (VLA-4) Integrin Induces Progenitor Cell Adhesion

(2013) Peter Vanderslice et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice

(2013) Toshihiko Sugiura et al.   Journal of Crohns & Colitis

Integrin Regulation during Leukocyte Recruitment

(2013) J. Herter et al.   JOURNAL OF IMMUNOLOGY

The Membrane-Proximal KXGFFKR Motif of  -Integrin Mediates Chemoresistance

(2013) C.-C. Liu et al.   MOLECULAR AND CELLULAR BIOLOGY

Mechanism for KRIT1 Release of ICAP1-Mediated Suppression of Integrin Activation

(2013) Weizhi Liu et al.   MOLECULAR CELL

Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study

(2013) Christian Wolf et al.   PLoS One

A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid

(2012) Masaki Setoguchi et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects

(2012) Martin S. Weber et al.   CURRENT PHARMACEUTICAL DESIGN

Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial

(2012) David H Miller et al.   LANCET NEUROLOGY

Integrins as therapeutic targets

(2012) Simon L. Goodman et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Integrin Targeted Therapeutics

(2012) Melissa Millard et al.   Theranostics

Notch signaling in acute lymphoblastic leukemia: any role for stromal microenvironment?

(2011) A. H. N. Kamdje et al.   BLOOD

New markers for minimal residual disease detection in acute lymphoblastic leukemia

(2011) E. Coustan-Smith et al.   BLOOD

Mechanisms of integrin activation and trafficking

(2011) Coert Margadant et al.   CURRENT OPINION IN CELL BIOLOGY

High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse

(2011) S. Shalapour et al.   HAEMATOLOGICA

Association between  4 integrin cytoplasmic tail and non-muscle myosin IIA regulates cell migration

(2011) L. A. R. Rosado et al.   JOURNAL OF CELL SCIENCE

Leukemia Stem Cells and Microenvironment: Biology and Therapeutic Targeting

(2011) Marina Y. Konopleva et al.   JOURNAL OF CLINICAL ONCOLOGY

Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4

(2011) M P Rettig et al.   LEUKEMIA

Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis

(2011) Saskia Thomas et al.   INFLAMMOPHARMACOLOGY

Potent in vivo suppression of inflammation by selectively targeting the high affinity conformation of integrin α4β1

(2010) Peter Vanderslice et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The bone marrow microenvironment as a sanctuary for minimal residual disease in CML

(2010) Rajesh R. Nair et al.   BIOCHEMICAL PHARMACOLOGY

Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers

(2010) S. Pillozzi et al.   BLOOD

Discovery of Very Late Antigen-4 (VLA-4, α4β1Integrin) Allosteric Antagonists

(2010) Alexandre Chigaev et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

(2010) David B Clifford et al.   LANCET NEUROLOGY

Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors

(2010) Andrew L. Muranyi et al.   LEUKEMIA RESEARCH

Integrins as therapeutic targets: lessons and opportunities

(2010) Dermot Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Integrins and Extracellular Matrix in Mechanotransduction

(2010) M. A. Schwartz   Cold Spring Harbor Perspectives in Biology

The Ins and Outs of Leukocyte Integrin Signaling

(2009) Clare L. Abram et al.   Annual Review of Immunology

Signal co-operation between integrins and other receptor systems

(2009) Charles H. Streuli et al.   BIOCHEMICAL JOURNAL

Cell Adhesion Antagonists

(2009) Darren G Woodside et al.   BIODRUGS

BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells

(2009) P. Ramirez et al.   BLOOD

Hematopoietic Stem Cells Do Not Depend on N-Cadherin to Regulate Their Maintenance

(2009) Mark J. Kiel et al.   Cell Stem Cell

Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches

(2009) Marina Konopleva et al.   DRUG RESISTANCE UPDATES

The role of natalizumab in hematopoietic stem cell mobilization

(2009) Frank Neumann et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Role of Minimal Residual Disease Monitoring in Adult and Pediatric Acute Lymphoblastic Leukemia

(2009) Dario Campana   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab

(2008) H. Bonig et al.   BLOOD

Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin

(2008) Brian G. Feagan et al.   Clinical Gastroenterology and Hepatology

An α4β1 integrin antagonist decreases airway inflammation in ovalbumin-exposed mice

(2008) Nicholas J. Kenyon et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Integrin-linked kinase - essential roles in physiology and cancer biology

(2008) P. C. McDonald et al.   JOURNAL OF CELL SCIENCE